Genmab A/S ADS has a trailing 12 month Price to Earnings (P/E) ratio of 12.7 while the S&P 500 average is 29.3 Its forward ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

Tensions in the Middle East shake Wall Street as healthcare stocks surge. Discover top gainers, Novo Nordisk's moves, and big pharma M&A updates.

For each study, definitions for symptomatic and severe disease are included in the appendix (pp 19–20). On the basis of sequencing or genotyping unless otherwise noted. Vaccine efficacy or ...

The latest health news covers FDA's extended review of KalVista's drug, UroGen's new bladder cancer treatment approval, ...

BioNTech announces CureVac acquisition for $1.25 billion in stock to strengthen cancer therapy pipeline and mRNA technology ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

Plus: Oracle posts strong quarterly results boosted by the company's artificial-intelligence investments. Biotech company BioNTech acquires CureVac. Adobe raises its full-year outlook after posting ...

Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its ...